Investigating the role of a PRMT5 in Ewing sarcoma and its potential as a target for treatment
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Studying how neuroblastoma cells and immune cells interact over time to see how the cancer adapts to treatment.
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.